Last update 11 Dec 2024
AChR x APP x GSK-3β x NF-κB x STAT3
Last update 11 Dec 2024
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
An open label, balanced, randomized, two-treatment, two period, two-sequence, single oral dose, crossover, bioequivalence study of Nitrocontin Controlled Release tablet 2.6 mg (Nitroglycerin) of Modi-Mundi Pharma Pvt. Ltd., in comparison with Nitromint® Retard Controlled Release tablet 2.6 mg (Nitroglycerin) of M/s Egis Pharma, Hungary in healthy, adult, human subjects under fasting condition. - NIL
A single site, open label study to evaluate the pharmacodynamic effects of a single dose of oral anatabine citrate in healthy adult volunteers.
100 Clinical Results associated with AChR x APP x GSK-3β x NF-κB x STAT3
Login to view more data
100 Translational Medicine associated with AChR x APP x GSK-3β x NF-κB x STAT3
Login to view more data
Login to view more data
Analysis
Perform a panoramic analysis of this field.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free